(Q64173538)
Statements
A Phase Ib Open-Label Study Evaluating the Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Bevacizumab and Immunotherapy When Administered in Patients With Gastrointestinal and Other Tumors (English)
0 references
30 September 2016
0 references
1 August 2019
0 references
51
0 references
18 year
0 references